• 1
    Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975-2001. Bethesda, MD: National Cancer Institute, 2004.
  • 2
    Eifel P, Axelson JA, Costa J, et al. National Institutes of Health consensus development conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst. 2001; 93: 979989.
  • 3
    Harlan LC, Abrams J, Warren JL, Clegg L, Stevens J, Ballard-Barbash R. Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol. 2002; 20: 18091817.
  • 4
    Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003; 138: 9097.
  • 5
    Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst. 2002; 94: 16261634.
  • 6
    Oestreicher N, Ramsey S, Linden H, et al. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med. 2005; 7: 380389.
  • 7
    Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care. 2005; 11: 313324.
  • 8
    Warren JL, Brown ML, Fay MP, Schussler N, Potosky AL, Riley GF. Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol. 2002; 20: 307316.
  • 9
    Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 1995; 87: 417426.
  • 10
    Barlow WE, Taplin SH, Yoshida CK, Buist DS, Seger D, Brown M. Cost comparison of mastectomy versus breast-conserving therapy for early-stage breast cancer. J Natl Cancer Inst. 2001; 93: 447455.
  • 11
    Hillner BE, Smith TJ. A model of chemotherapy in node-negative breast cancer. J Natl Cancer Inst Monogr. 1992; (11): 143149.
  • 12
    Kattlove H, Liberati A, Keeler E, Brook RH. Benefits and costs of screening and treatment for early breast cancer. Development of a basic benefit package. JAMA. 1995; 273: 142148.
  • 13
    Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care. 1995; 33: 828841.
  • 14
    Lober J, Sogaard J, Mouridsen HT, Jorgensen J. Treatment costs of adjuvant cytotoxic therapy in premenopausal breast cancer patients. Acta Onc. 1988; 27: 767771.
  • 15
    Lokich JJ, Moore CL, Anderson NR. Comparison of costs for infusion versus bolus chemotherapy administration—part two. Use of charges versus reimbursement for cost basis. Cancer. 1996; 78: 300803.
  • 16
    Hennekens C, Buring J. Epidemiology in medicine. Boston: Little, Brown and Company, 1987.
  • 17
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373383.
  • 18
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613619.
  • 19
    Young JL, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA. SEER summary staging manual - 2000: codes and coding instructions. NIH Pub. No. 01-4969. Bethesda, MD: National Cancer Institute, 2001.
  • 20
    Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40: IV-5561.
  • 21
    Etzioni R, Urban N, Baker M. Estimating the costs attributable to a disease with application to ovarian cancer. J Clin Epidemiol. 1996; 49: 95103.
  • 22
    Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics. 1997; 53: 419434.
  • 23
    Gold ME, Russell LB, Siegel JE, Weinstein ME. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
  • 24
    Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev. 1997; 18: 5176.
  • 25
    van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347: 19992009.